Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation

British Journal of Clinical Pharmacology

Volumn 74, Issue 1, 2012, Pages 161-170

  Schmidt, Morten ^a   Johansen, Martin B ^a   Maeng, Michael ^a   Kaltoft, Anne ^a   Jensen, Lisette O ^b   Tilsted, Hans Henrik ^a   Bøtker, Hans E ^a   Baron, John A ^c   Sørensen, Henrik Toft ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Angioplasty; Cardiovascular disease; Clopidogrel; Drug interactions; Statins; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 3A4; FIBRINOGEN RECEPTOR ANTAGONIST; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SIMVASTATIN; THIENOPYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BARE METAL STENT; BIBLIOGRAPHIC DATABASE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DENMARK; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEMALE; FOLLOW UP; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTENSION; IMPLANTATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TABLET; TARGET LESION REVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; CYTOCHROME P-450 CYP3A; DENMARK; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; REGRESSION ANALYSIS; RISK FACTORS; STENTS; TICLOPIDINE; TIME FACTORS;

EID: 84862139558     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04169.x     Document Type: Article

References (47)

1. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-21.
2. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57: 1251-63.
3. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31: 53-9.
4. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-7.
5. Neubauer H, Günesdogan B, Hanefeld C, Spiecker M, Mügge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study. Eur Heart J 2003; 24: 1744-9.
6. Mach F, Senouf D, Fontana P, Boehlen F, Reber G, Daali Y, de Moerloose P, Sigwart U. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest 2005; 35: 476-81.
7. Han YL, Zhang ZL, Li Y, Wang SL, Jing QM, Wang ZL, Wang DM. Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting: a randomized controlled trial. Zhonghua Yi Xue Za Zhi 2009; 89: 2240-4.
8. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ. Clopidogrel for the Reduction of Events During Observation I. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-4.
9. Saw J, Brennan DM, Steinhubl SR, Bhatt DL, Mak KH, Fox K, Topol EJ, on behalf of the CHARISMA Investigators. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007; 50: 291-5.
10. Lotfi A, Schweiger M, Giugliano G, Murphy S, Cannon C. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients - A Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Am Heart J 2008; 155: 954-8.
11. Trenk D, Hochholzer W, Frundi D, Stratz C, Valina CM, Bestehorn H-P, Büttner HJ, Neumann F-J. Impact of cytochrome P450 3A4-metabolized statins on the anti-platelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008; 99: 174-81.
12. Mukherjee DF, Kline-Rogers E, Fang J, Munir K, Eagle KA. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 2005; 91: 23-6.
13. Geisler T, Zurn C, Paterok M, Gohring-Frischholz K, Bigalke B, Stellos K, Seizer P, Kraemer BF, Dippon J, May AE, Herdeg C, Gawaz M. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J 2008; 29: 1635-43.
14. Wienbergen H, Gitt AK, Schiele R, Juenger C, Heer T, Meisenzahl C, Limbourg P, Bossaller C, Senges J, Group MPS. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92: 285-8.
15. Blagojevic A, Delaney JAC, Lévesque LE, Dendukuri N, Boivin J-F, Brophy JM. Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study. Pharmacoepidemiol Drug Saf 2009; 18: 362-9.
16. Greenland S, Lash TL, Rothman KJ. Concepts of Interaction. In: Modern Epidemiology, 3rd edn., eds Rothman KJ, Greenland S, Lash TL. Philadelphia, PA: Lippincott Williams & Wilkins, 2008; 71-86.
17. Schmidt M, Maeng M, Jakobsen CJ, Madsen M, Thuesen L, Nielsen PH, Bøtker H, Sørensen HT. Existing data sources for clinical epidemiology: The Western Denmark Heart Registry. Clinical Epidemiology 2010; 2: 137-44.
18. Danish Medicines Agency. Over-the-counter medicine and reimbursement criteria in Denmark [online]. Available at (last Accessed 1 February 2012).
19. Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006; 53: 441-9.
20. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997; 44: 445-8.
21. Danish Medicines Agency. Available drugs and package sizes on the Danish drug market [online]. Available at (last Accessed 1 February 2012).
22. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109: III50-7.
23. Andersen TF, Madsen M, Jorgensen J, Mellemkjaer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263-8.
24. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003; 56: 124-30.
25. Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull 1999; 46: 354-7.
26. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990; 82: 1193-202.
27. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
28. Piorkowski M, Weikert U, Schwimmbeck PL, Martus P, Schultheiss HP, Rauch U. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. Thromb Haemost 2004; 92: 614-20.
29. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, Tanguay JF, Steinhubl SR, Berger PB, O'Connor CM, Hennekens CH. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004; 164: 2051-7.
30. Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, Ernest CS, Salazar DE, Konkoy CS, Winters KJ. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy 2008; 28: 1483-94.
31. Smith SM, Judge HM, Peters G, Storey RF. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets 2004; 15: 465-74.
32. Malmström RE, Östergren J, Jørgensen L, Hjemdahl P. Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. J Intern Med 2009; 266: 457-66.
33. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004; 109: 1335-8.
34. Mitsios JV, Papathanasiou AI, Elisaf M, Goudevenos JA, Tselepis AD. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20mg/day) for 5 weeks in patients with acute coronary syndromes. Platelets 2005; 16: 287-92.
35. Vinholt P, Poulsen TS, Korsholm L, Kristensen SR, Hallas J, Damkier P, Mickley H. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thromb Haemost 2005; 94: 438-43.
36. Wenaweser P, Windecker S, Billinger M, Cook S, Togni M, Meier B, Haeberli A, Hess OM. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. Am J Cardiol 2007; 99: 353-6.
37. Gorchakova O, von Beckerath N, Gawaz M, Mocz A, Joost A, Schömig A, Kastrati A. Antiplatelet effects of a 600mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004; 25: 1898-902.
38. Motovska Z, Widimsky P, Petr R, Bilkova D, Marinov I, Simek S, Kala P; PRAGUE-8 Study Investigators. Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking 'paradox'. J Cardiovasc Pharmacol 2009; 53: 368-72.
39. Müller I, Besta F, Schulz C, Li Z, Massberg S, Gawaz M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003; 108: 2195-7.
40. Brophy J, Babapulle M, Costa V, Rinfret S. A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. Am Heart J 2006; 152: 263-9.
41. Bhindi R, Ormerod O, Newton J, Banning AP, Testa L. Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 2008; 101: 915-25.
42. Nair PK, Mulukutla SR, Marroquin OC. Stents and statins: history, clinical outcomes and mechanisms. Expert Rev Cardiovasc Ther 2010; 8: 1283-95.
43. Schneeweiss S, Patrick AR, Stürmer T, Brookhart MA, Avorn J, Maclure M, Rothman KJ, Glynn RJ. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007; 45: S131-42.
44. Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 2005; 162: 1016-23.
45. Stürmer T, Jonsson Funk M, Poole C, Brookhart MA. Nonexperimental comparative effectiveness research using linked healthcare databases. Epidemiology 2011; 22: 298-301.
46. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
47. Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A, Wilmer C, Topol EJ, Credo Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.